We investigated in 70 women over a period of 6 months the influence of different dose regimen of the potent LH-RH analogue Buserelin (HOE 766: 400, 200, 100 micrograms per day) on pituitary and ovarian function. The histological findings of the endometrial biopsy specimen (n = 109) were correlated with the hormonal profiles and the bleeding pattern. There was an evident dose-related inhibition of ovulation or corpus luteum integrity. A regular bleeding pattern was found more often in the lower dose groups. Unopposed estrogen effects recognized by prolonged endometrial stimulation were mainly registered in women with amenorrhea induced by 400 micrograms buserelin. Regression of endometrial stimulation could be observed during the six months period of medication. If higher dose regimen will lead to a more consistent inhibition of ovarian function, remains to be investigated.

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-2008-1036992DOI Listing

Publication Analysis

Top Keywords

lh-rh analogue
8
analogue buserelin
8
dose regimen
8
ovarian function
8
bleeding pattern
8
endometrial stimulation
8
[the influence
4
influence long-term
4
long-term medication
4
medication lh-rh
4

Similar Publications

The efficacy and safety of rhGH treatment combined with letrozole/GnRHa in adolescent boys.

BMC Pediatr

January 2025

Department of Endocrinology, Genetics and Metabolism, Fuzhou First General Hospital Affiliated with Fujian Medical University, Fuzhou Children's Hospital of Fujian Medical University, Fuzhou, 350005, China.

Objective: In boys during puberty who were undergoing recombinant human growth hormone (rhGH) treatment, we compared the therapeutic efficacy on growth, and any adverse reactions, of co-therapy with either letrozole or gonadotropin-releasing hormone analog (GnRHa).

Methods: Fifty-six pubertal growth hormone deficiency (GHD) boys were studied, they were treated with the combination of letrozole and rhGH (letrozole group, n = 28) or the combination of GnRHa and rhGH (GnRHa group, n = 28) for at least one year. Eighteen patients in the letrozole group and seventeen patients in the GnRHa group attained final adult height (FAH).

View Article and Find Full Text PDF

Disseminated peritoneal leiomyomatosis (DPL) is a rare entity. It is a benign disease but can mimic disseminated malignancy with extensive disease at multiple sites within the abdominopelvic cavity. The primary contributing factor is postulated to be peritoneal spillage of benign leiomyoma, especially after laparoscopic intervention, although hormonal influences might also play a role.

View Article and Find Full Text PDF

The judicious selection of ovulation inhibitors in ovarian stimulation protocols is crucial for the success of assisted reproductive technology (ART). Herein, we investigate the dose-dependent effects of chlormadinone acetate (CMA) and cetrorelix, two distinct ovulation inhibitors, on oocyte maturation in patients with normal ovarian reserve, using univariable and multivariable Poisson regression analyses. Patients undergoing progestin-primed ovarian stimulation (PPOS) with CMA (n = 299) or gonadotropin-releasing hormone antagonist (GnRH-ant) with cetrorelix (n = 605) during their initial in vitro fertilization cycle were enrolled at our center from March 2018 to October 2020 (N = 904).

View Article and Find Full Text PDF

Context: Progestins have recently been used as an alternative for gonadotropin-releasing hormone (GnRH) analogues to prevent premature luteinizing hormone surge due to the application of vitrification technology. However, the long-term efficacy and safety of a progestin-primed ovarian stimulation (PPOS) regimen, including oocyte competence, cumulative live birth rate (LBR), and offspring outcomes, remain to be investigated.

Objective: To compare cumulative LBR of preimplantation genetic testing (PGT) cycles between a PPOS regimen and GnRH analogues.

View Article and Find Full Text PDF

Hormonal factors play an essential role as an underlying causative factor of oligoasthenoteratozoospermia (OAT), and these patients can benefit from hormonal medications that modulate the hypothalamic-pituitary-gonadal axis. This review aims to outline the various medications used as hormonal therapy in treating infertile men with OAT. This manuscript focuses on essential hormonal evaluation, identifying men who would benefit from treatment, selecting the appropriate medication, determining the duration of therapy, and evaluating hormonal treatment outcomes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!